Previous close | 17.09 |
Open | 17.42 |
Bid | 12.46 x 200 |
Ask | 17.45 x 100 |
Day's range | 17.00 - 17.71 |
52-week range | 7.64 - 30.19 |
Volume | |
Avg. volume | 969,701 |
Market cap | 1.005B |
Beta (5Y monthly) | -0.06 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.13 |
Earnings date | 08 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 33.00 |
Key Insights Given the large stake in the stock by institutions, Cullinan Therapeutics' stock price might be vulnerable...
Objective response rate of 39% with manageable safety profile in patients with non-small cell lung cancer (NSCLC) harboring EGFR Exon 20 insertion mutations treated with zipalertinib who had progressed after prior amivantamab treatmentCAMBRIDGE, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced positive initial data in patients receiving zipalertinib after pr
CAMBRIDGE, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed, Chief Executive Officer and Jeffrey Jones, MD, MBA, Chief Medical Officer, will participate in a fireside chat at the TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA, being held virtually on May 28 and 29, 2024. The fireside chat is scheduled for Wednesday, M